Skip to main content

Hugh Grant, chairman and CEO of Monsanto, participates in a panel discussion at the 2015 Fortune Global Forum.

ELIJAH NOUVELAGE/REUTERS

Monsanto Co’s Chief Executive Officer Hugh Grant will step down when Bayer AG completes the takeover of the U.S. seeds company, making way for Bayer executive Liam Condon to lead the combined crop sciences business.

Grant became CEO in 2003 and will leave following the close of the deal, along with other senior executives including Chief Financial Officer Pierre Courduroux and Chief Technology Officer Robert Fraley, Monsanto said on Monday.

German conglomerate Bayer is preparing to close its $62.5 billion takeover of Monsanto this quarter, giving it control of more than 25 per cent of the world’s seed and pesticides market.

Story continues below advertisement

Condon, the head of its Crop Science division, will stay in that role after the Monsanto deal is wrapped up, Bayer said.

Monsanto’s Chief Operating Officer Brett Begemann will assume the same role at Bayer’s enlarged Crop Science division, and will be based in St. Louis.

Bayer has been divesting assets to win over antitrust regulators for its proposed takeover.

Grant said he has “made the decision to pursue new opportunities following the closing” of the deal but did not give any further details.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter